This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hodge, J. C. Articles by Lindholm, P. F. Search for Related Content PubMed PubMed Citation Articles by Hodge, J. C. Articles by Lindholm, P. F.

Requirement of RhoA Activity for Increased Nuclear Factor B Activity and PC-3 Human Prostate Cancer Cell Invasion¹

Department of Pathology, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611 [J. C. H., P. F. L.], and Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226 [J. B., S. K., A. K-B.]

To determine the molecular mechanisms of aggressive prostate cancer behavior, we studied RhoGTPases in high and low invasive variants of PC-3 prostate cancer cells. Prior studies with these cells revealed that elevated nuclear factor B (NF-B) expression and activity were necessary for the highly invasive phenotype. In the current study, increased RhoA expression was found in the PC-3 highly invasive cells as compared with the PC-3 low invasive cells through cDNA array and Western blot analyses. Similarly, RhoA activity, as measured by the Rhotekin binding assay, was elevated in the PC-3 highly invasive cells. Transfection of these highly invasive cells with dominant negative RhoA N19 or treatment with 1.0 µg/ml RhoA inhibitor C3 exoenzyme demonstrated that RhoA activity was necessary for both NF-B activity and cellular invasion of a Matrigel reconstituted basement membrane. Furthermore, stable transfection of the PC-3 highly invasive cells with constitutively active RhoA Q63L resulted in activation of NF-B activity and Matrigel invasion, effects reversed by treatment of the cells with C3 exoenzyme. RhoA was also shown to act through the motility component of the invasion process. RhoA activity was therefore both necessary and sufficient for the elevated NF-B, invasion, and motility activities of the PC-3 highly invasive cells. These findings suggest molecular targets to control cancer cell invasion and aid in the development of definitive tools for predicting the invasive and metastatic potential of cancer cells.

This article has been cited by other articles:

				Y. Ozawa and H. Kobori Crucial role of Rho-nuclear factor-{kappa}B axis in angiotensin II-induced renal injury Am J Physiol Renal Physiol, July 1, 2007; 293(1): F100 - F109. [Abstract] [Full Text] [PDF]

				S. N. Sahu, S. Nunez, G. Bai, and A. Gupta Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells Am J Physiol Cell Physiol, June 1, 2007; 292(6): C2288 - C2296. [Abstract] [Full Text] [PDF]

				S. Shimizu, M. Tahara, S. Ogata, K. Hashimoto, K. Morishige, K. Tasaka, and Y. Murata Involvement of nuclear factor-kB activation through RhoA/Rho-kinase pathway in LPS-induced IL-8 production in human cervical stromal cells Mol. Hum. Reprod., March 1, 2007; 13(3): 181 - 187*. [Abstract] [Full Text] [PDF]

				P. Kelly, L. N. Stemmle, J. F. Madden, T. A. Fields, Y. Daaka, and P. J. Casey A Role for the G12 Family of Heterotrimeric G Proteins in Prostate Cancer Invasion J. Biol. Chem., September 8, 2006; 281(36): 26483 - 26490. [Abstract] [Full Text] [PDF]

				C.-M. Wong, J. W.-P. Yam, Y.-P. Ching, T.-O. Yau, T. H.-Y. Leung, D.-Y. Jin, and I. O.-L. Ng Rho GTPase-Activating Protein Deleted in Liver Cancer Suppresses Cell Proliferation and Invasion in Hepatocellular Carcinoma Cancer Res., October 1, 2005; 65(19): 8861 - 8868. [Abstract] [Full Text] [PDF]

				V. Fradet, L. Lessard, L. R. Begin, P. Karakiewicz, A.-M. M. Masson, and F. Saad Nuclear Factor-{kappa}B Nuclear Localization Is Predictive of Biochemical Recurrence in Patients with Positive Margin Prostate Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8460 - 8464. [Abstract] [Full Text] [PDF]

				M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]